Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Abstract 6906: c-Myc inhibition through targeting MMK3 and c-Myc interaction overcomes acquired resistance to third generation EGFR inhibitors in the treatment of EGFR mutant lung cancer

Zhen Chen, Karin A Vallega, Dongsheng Wang, Haian Fu, Suresh S Ramalingam, Andrey A Ivanov, Shi-Yong Sun

Cancer Res (2025) 85 (8_Supplement_1): 6906.

https://doi.org/10.1158/1538-7445.AM2025-6906

Published: 21 April 2025

View articletitled, Abstract 6906: c-Myc inhibition through targeting MMK3 and c-Myc interaction overcomes acquired resistance to third generation EGFR inhibitors in the treatment of EGFR mutant lung cancer

Journal Articles

Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer

Junghui Koo, Chang-Soo Seong, Rebecca E. Parker, Amy Herrera, Bhakti Dwivedi, Robert A. Arthur, Ashok Reddy Dinasarapu, Henry Richard Johnston, Henry Claussen, Carol Tucker-Burden, Suresh S. Ramalingam, Haian Fu, Wei Zhou, Adam I. Marcus, Melissa Gilbert-Ross

Cancer Res (2024) 84 (22): 3761–3771.

https://doi.org/10.1158/0008-5472.CAN-23-2631

Published: 15 November 2024

View articletitled, Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer

Includes: Multimedia, Supplementary data

Journal Articles

Abstract 2089: A pro-oncogenic RAS-GTP:RAN-GAP complex facilitates nuclear protein export and has clinical implications

Brajendra K. Tripathi, Nicole H. Hirsh, David Hansen, Xiaolan Qian, Marian E. Durkin, Dunrui Wang, Alex G. Papageorge, Ross Lake, Yvonne A. Evrard, Adam Marcus, Suresh S. Ramalingam, Mary Dasso, Karen Vousden, James H. Doroshow, Kylie J. Walters, Douglas R. Lowy

Cancer Res (2024) 84 (6_Supplement): 2089.

https://doi.org/10.1158/1538-7445.AM2024-2089

Published: 22 March 2024

View articletitled, Abstract 2089: A pro-oncogenic RAS-GTP:RAN-GAP complex facilitates nuclear protein export and has clinical implications

Journal Articles

Abstract 4756: Targeting DNA topoisomerase II to manage acquired resistance to third generation EGFR tyrosine kinase inhibitors in the treatment of EGFR mutant NSCLC

Zhen Chen, Karin A. Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang, Ticiana A. Leal, Suresh S. Ramalingam, Shi-Yong Sun

Cancer Res (2024) 84 (6_Supplement): 4756.

https://doi.org/10.1158/1538-7445.AM2024-4756

Published: 22 March 2024

View articletitled, Abstract 4756: Targeting DNA topoisomerase II to manage acquired resistance to third generation EGFR tyrosine kinase inhibitors in the treatment of EGFR mutant NSCLC

Journal Articles

Abstract 4047: Unraveling synergistic therapeutic strategies involving FAK inhibition and immunotherapy using anti-PD1 antibody in KRAS and LKB1-driven lung cancer

Junghui Koo, Carol Tucker-Burden, Melissa Roy, Chunzi Huang, Wei Zhou, Melissa Gilbert-Ross, Haian Fu, Suresh S. Ramalingam, Adam I. Marcus

Cancer Res (2024) 84 (6_Supplement): 4047.

https://doi.org/10.1158/1538-7445.AM2024-4047

Published: 22 March 2024

View articletitled, Abstract 4047: Unraveling synergistic therapeutic strategies involving FAK inhibition and immunotherapy using anti-PD1 antibody in KRAS and LKB1-driven lung cancer

Journal Articles

Abstract CT008: Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100

Cancer Res (2022) 82 (12_Supplement): CT008.

https://doi.org/10.1158/1538-7445.AM2022-CT008

Published: 15 June 2022

View articletitled, Abstract CT008: Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100

Journal Articles

Abstract 428: Therapeutic potential of the novel SHP2 degrader, SHP2-D26, alone or in combination, in the treatment of lung cancer

Yunful Deng, Guangzhi Ma, Karin A. Vallega, Dongsheng Wang, Mingliang Wang, Changwei Wang, Shaomeng Wang, Suresh S. Ramalingam, Shi-Yong Sun

Cancer Res (2022) 82 (12_Supplement): 428.

https://doi.org/10.1158/1538-7445.AM2022-428

Published: 15 June 2022

View articletitled, Abstract 428: Therapeutic potential of the novel SHP2 degrader, SHP2-D26, alone or in combination, in the treatment of lung cancer

Journal Articles

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Lei Zhu, Zhen Chen, Hongjing Zang, Songqing Fan, Jiajia Gu, Guojing Zhang, Kevin D.-Y. Sun, Qiming Wang, Yong He, Taofeek K. Owonikoko, Suresh S. Ramalingam, Shi-Yong Sun

Cancer Res (2021) 81 (18): 4822–4834.

https://doi.org/10.1158/0008-5472.CAN-21-0556

Published: 15 September 2021

View articletitled, Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Includes: Supplementary data

Journal Articles

Abstract 1671: Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small Cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell memory subsets

Venkat Mohanram, Natalya Belkina, Angelina R. Bisconte, Jonathan W. Goldman, Gregory J. Gerstner, Missak Haigentz, Thomas Stinchcombe, Balazs Halmos, Surya Vangala, Victor Kabala, Dinesh Simkhada, Cristiane Metran, Darren Davis, Megan Parsi, Andres A. Gutierrez, Deborah Phippard, Suresh S. Ramalingam

Cancer Res (2021) 81 (13_Supplement): 1671.

https://doi.org/10.1158/1538-7445.AM2021-1671

Published: 01 July 2021

View articletitled, Abstract 1671: Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small Cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell memory subsets

Journal Articles

Abstract 2040: Virtual patient simulation improves first-line treatment selection in advanced EGFR-mutated NSCLC

Michelle A. Worst, Rich Caracio, Donna L. Topping, Suresh S. Ramalingam

Cancer Res (2020) 80 (16_Supplement): 2040.

https://doi.org/10.1158/1538-7445.AM2020-2040

Published: 15 August 2020

View articletitled, Abstract 2040: Virtual patient simulation improves first-line treatment selection in advanced EGFR-mutated NSCLC

Journal Articles

Mcl-1 Interacts with Akt to Promote Lung Cancer Progression

Guo Chen, Dongkyoo Park, Andrew T. Magis, Madhusmita Behera, Suresh S. Ramalingam, Taofeek K. Owonikoko, Gabriel L. Sica, Keqiang Ye, Chao Zhang, Zhengjia Chen, Walter J. Curran, Xingming Deng

Cancer Res (2019) 79 (24): 6126–6138.

https://doi.org/10.1158/0008-5472.CAN-19-0950

Published: 13 December 2019

View articletitled, Mcl-1 Interacts with Akt to Promote Lung Cancer Progression

Includes: Supplementary data

Journal Articles

Abstract 1277: Honokiol, a natural product, overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib

Hongjing ZANG, Songqing Fan, Jack Arbiser, Taofeek K. Owonikoko, Suresh S. Ramalingam, Shi-Yong Sun

Cancer Res (2019) 79 (13_Supplement): 1277.

https://doi.org/10.1158/1538-7445.AM2019-1277

Published: 01 July 2019

View articletitled, Abstract 1277: Honokiol, a natural product, overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib

Journal Articles

Abstract 73: Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib

Jiajia Gu, Xia He, Nupam P. Mahajan, Taofeek K. Owonikoko, Suresh S. Ramalingam, Shi-Yong Sun

Cancer Res (2019) 79 (13_Supplement): 73.

https://doi.org/10.1158/1538-7445.AM2019-73

Published: 01 July 2019

View articletitled, Abstract 73: Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib

Journal Articles

Abstract 77: Therapeutic potential of ERK inhibitors in overcoming acquired resistance to third generation EGFR tyrosine kinase inhibitors

Yiting Li, Guoqing Qian, Taofeek K. Owonikoko, Suresh S. Ramalingam, Shi-Yong Sun

Cancer Res (2019) 79 (13_Supplement): 77.

https://doi.org/10.1158/1538-7445.AM2019-77

Published: 01 July 2019

View articletitled, Abstract 77: Therapeutic potential of ERK inhibitors in overcoming acquired resistance to third generation EGFR tyrosine kinase inhibitors

Journal Articles

Abstract CT034: Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study

Suresh S. Ramalingam, Hideo Saka, Myung-Ju Ahn, Helena Yu, Helena Yu, Leora Horn, Toyoaki Hida, Mireille Cantarini, Remy Verheijen, Jonathan Wessen, Geoffrey Oxnard, Yuichiro Ohe

Cancer Res (2019) 79 (13_Supplement): CT034.

https://doi.org/10.1158/1538-7445.AM2019-CT034

Published: 01 July 2019

View articletitled, Abstract CT034: Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study

Journal Articles

Abstract CT041: Identification of gene signatures associated with response in a Phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy

Peter Ordentlich, Lei Wang, David Tamang, Amy H. Sullivan, Sally E. Church, Dan Rozelle, Michael L. Meyers, Suresh S. Ramalingam, Matthew D. Hellmann

Cancer Res (2019) 79 (13_Supplement): CT041.

https://doi.org/10.1158/1538-7445.AM2019-CT041

Published: 01 July 2019

View articletitled, Abstract CT041: Identification of gene signatures associated with response in a Phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy

Journal Articles

Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response

Cancer Res (2019) 79 (13_Supplement): CT195.

https://doi.org/10.1158/1538-7445.AM2019-CT195

Published: 01 July 2019

View articletitled, Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response

Journal Articles

Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227

Cancer Res (2018) 78 (13_Supplement): CT077.

https://doi.org/10.1158/1538-7445.AM2018-CT077

Published: 01 July 2018

View articletitled, Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227

Journal Articles

Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568

Suresh S. Ramalingam, Matthew D. Hellmann, Mark M. Awad, Hossein Borghaei, Justin Gainor, Julie Brahmer, David R. Spigel, Martin Reck, Kenneth J. O'Byrne, Luis Paz-Ares, Kim Zerba, Xuemei Li, William J. Geese, George Green, Brian Lestini, Joseph D. Szustakowski, Han Chang, Neal Ready

Cancer Res (2018) 78 (13_Supplement): CT078.

https://doi.org/10.1158/1538-7445.AM2018-CT078

Published: 01 July 2018

View articletitled, Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568

Journal Articles

Abstract CT126: Soluble HLA-G and -E (sHLA-G/E) as potential biomarkers of clinical outcomes in patients (pts) with advanced, refractory squamous (SQ) NSCLC treated with nivolumab (NIVO): CheckMate 063

Vera Rebmann*, Wilfried E. Eberhardt*, Naiyer Rizvi, Scott J. Antonia, David Planchard, Federico Cappuzzo, Julien Mazières, Gérard Zalcman, Hervé Lena, Jürgen Wolf, Leora Horn, Thomas Stinchcombe, Grace Dy, Anne Blackwood-Chirchir, Chelsea Jin, William J. Geese, Suresh S. Ramalingam, *Authors contributed equally to the current work

Cancer Res (2017) 77 (13_Supplement): CT126.

https://doi.org/10.1158/1538-7445.AM2017-CT126

Published: 01 July 2017

View articletitled, Abstract CT126: Soluble HLA-G and -E (sHLA-G/E) as potential biomarkers of clinical outcomes in patients (pts) with advanced, refractory squamous (SQ) NSCLC treated with nivolumab (NIVO): CheckMate 063

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Abstract 6906: c-Myc inhibition through targeting MMK3 and c-Myc interaction overcomes acquired resistance to third generation EGFR inhibitors in the treatment of EGFR mutant lung cancer

Live-Cell Invasive Phenotyping Uncovers ALK2 as a Therapeutic Target in LKB1-Mutant Lung Cancer

Abstract 2089: A pro-oncogenic RAS-GTP:RAN-GAP complex facilitates nuclear protein export and has clinical implications

Abstract 4756: Targeting DNA topoisomerase II to manage acquired resistance to third generation EGFR tyrosine kinase inhibitors in the treatment of EGFR mutant NSCLC

Abstract 4047: Unraveling synergistic therapeutic strategies involving FAK inhibition and immunotherapy using anti-PD1 antibody in KRAS and LKB1-driven lung cancer

Abstract CT008: Long-term outcomes with sotorasib in pretreated KRASp.G12C-mutated NSCLC: 2-year analysis of CodeBreaK100

Abstract 428: Therapeutic potential of the novel SHP2 degrader, SHP2-D26, alone or in combination, in the treatment of lung cancer

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib

Abstract 1671: Evaluation of total PD-1 expression using multi-color flow cytometry in metastatic non-small Cell lung cancer patients treated with multi-neoantigen vector (ADXS-503) alone and in combination of pembrolizumab to assess T-cell & T-cell memory subsets

Abstract 2040: Virtual patient simulation improves first-line treatment selection in advanced EGFR-mutated NSCLC

Mcl-1 Interacts with Akt to Promote Lung Cancer Progression

Abstract 1277: Honokiol, a natural product, overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib

Abstract 73: Inhibition of ACK1 delays and overcomes acquired resistance of EGFR mutant NSCLC cells to the third generation EGFR inhibitor, osimertinib

Abstract 77: Therapeutic potential of ERK inhibitors in overcoming acquired resistance to third generation EGFR tyrosine kinase inhibitors

Abstract CT034: Osimertinib plus selumetinib for patients (pts) with EGFR-mutant (EGFRm) NSCLC following disease progression on an EGFR-TKI: Results from the Phase Ib TATTON study

Abstract CT041: Identification of gene signatures associated with response in a Phase II trial of entinostat (ENT) plus pembrolizumab (PEMBRO) in non-small cell lung cancer (NSCLC) patients whose disease has progressed on or after anti-PD-(L)1 therapy

Abstract CT195: Long-term survival outcomes with nivolumab (NIVO) in pts with previously treated advanced non-small cell lung cancer (NSCLC): Impact of early disease control and response

Abstract CT077: Nivolumab (nivo) + ipilimumab (ipi) vs platinum-doublet chemotherapy (PT-DC) as first-line (1L) treatment (tx) for advanced non-small cell lung cancer (NSCLC): initial results from CheckMate 227

Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568

Abstract CT126: Soluble HLA-G and -E (sHLA-G/E) as potential biomarkers of clinical outcomes in patients (pts) with advanced, refractory squamous (SQ) NSCLC treated with nivolumab (NIVO): CheckMate 063

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only